Aptevo Therapeutics (APVO) Expected to Announce Earnings on Monday

Aptevo Therapeutics (NASDAQ:APVO) is expected to post its results before the market opens on Monday, August 10th. Analysts expect Aptevo Therapeutics to post earnings of ($6.02) per share for the quarter.

Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($6.41) EPS for the quarter, hitting the consensus estimate of ($6.41). On average, analysts expect Aptevo Therapeutics to post $-23 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Aptevo Therapeutics Price Performance

Shares of NASDAQ:APVO traded down $0.19 during mid-day trading on Monday, reaching $3.92. 3,073 shares of the company traded hands, compared to its average volume of 100,354. The company’s 50 day moving average price is $4.59 and its 200-day moving average price is $5.44. The firm has a market cap of $4.88 million, a PE ratio of -0.02 and a beta of 1.66. Aptevo Therapeutics has a 52 week low of $3.68 and a 52 week high of $50.40.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Aptevo Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Aptevo Therapeutics has a consensus rating of “Hold”.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Aptevo Therapeutics stock. Virtu Financial LLC purchased a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned about 1.16% of Aptevo Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 8.06% of the stock is currently owned by hedge funds and other institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.